Update on the clinical trial of VTS-270: The NPC Study

Please join us for a webinar as Dr. Forbes Porter of the NIH shares the 18 month data from the Phase 1/2 evaluation of intrathecal 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick disease, type C1

When: Friday, May 20th 12:30 – 1:00pm ET
Where: Webinar – please email carrie@vtessepharma.com to register. If you cannot make the live webinar please indicate that in your email and we will send you the recorded webinar.